**Suppl 1.** Supplement table S1: PFS and OS (months) by patient characteristics

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | PFS (in months) | | OS (in months) | |
|  | Median | P (Log-rank) | Median | P (Log-rank) |
| Gender  Female (N = 81)  Male (N = 79) | 47  35 | 0.7852 | 91  -- | 0.81 |
| Race  African American (N = 38)  Caucasian (N = 122) | 29  47 | 0.4730 | --  68 | 0.79 |
| Diagnosis  Lung cancer (N = 106)  Melanoma (N = 54) | 29  -- | 0.0290 | 91  42 | 0.75 |
| Line of treatment  First-line (N = 112)  Second-line (N = 48) | 26  74 | 0.0002 | --  91 | 0.21 |
| Previous Systemic Therapy  No (N = 98)  Yes (N = 62) | 33  41 | 0.9278 | 42  91 | 0.50 |
| Combination chemotherapy  No (N = 122)  Yes (N = 38) | 47  17 | 0.0023 | 91  -- | 0.49 |
| irAE  No (N = 114)  Yes (N = 46) | 41  35 | 0.7668 | --  35 | 0.18 |
| Age group  Younger than 65 years (N = 82)  65 years or older (N = 78) | 35  41 | 0.3669 | --  68 | 0.93 |
| Stage  2 or 3 (N = 57)  4 (N = 103) | --  33 | 0.1518 | --  68 | 0.09 |
| Level of burden  Low (N = 80)  High (N = 80) | --  29 | 0.0166 | 91  68 | 0.13 |
| WBC level (K/uL)  Less than or equal to 10 (N = 121)  Higher than 10 (N = 39) | 47  26 | 0.0247 | --  42 | 0.05 |
| ALC level (K/uL)  Less than or equal to 600 (N = 16)  Higher than 600 (N = 144)  Less than or equal to 1000 (N = 48)  Higher than 1000 (N = 112)  Less than or equal to 2000 (N = 126)  Higher than 2000 (N = 34) | 26  41  33  41  35  -- | 0.6126  0.4113  0.6890 | 68  91  68  91  91  -- | 0.91  0.88  0.96 |
| PLT/ALC ratio  Less than or equal to 150 (N = 63)  Higher than 150 (N = 97) | 33  35 | 0.5685 | --  91 | 0.99 |
| RE/Non-RE  Non-RE (N = 26)  RE (N = 19) | 74  35 | 0.4051 | 26  35 | 0.81 |